Study Comparing Pirtobrutinib with Venetoclax and Rituximab to Venetoclax and Rituximab Alone in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Inclusion Criteria

• Have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) that needs treatment.
• Have received at least one previous treatment, which may include a specific type of medication called a covalent BTK inhibitor.
• Have a platelet count of at least 50 x 10⁹/L, hemoglobin level of at least 8 g/dL, and a neutrophil count of at least 1.0 x 10⁹/L.
• Have good organ function.
• Have an ECOG performance status score between 0 and 2, indicating full activity or some restriction in strenuous activities.
• Have an estimated creatinine clearance of at least 30 mL/min, indicating adequate kidney function.

Exclusion Criteria

• Have had a transformation to a more aggressive form of lymphoma known as Richter's transformation.
• Have previously been treated with a non-covalent BTK inhibitor.
• Require blood thinners like warfarin or other Vitamin K antagonists.
• Are currently taking strong medications that affect liver enzymes (CYP3A4 inhibitors or inducers).
• Have previously been treated with Venetoclax.
• Have cancer that has spread to the brain or spinal cord.
• Have an active, uncontrolled infection.
• Have HIV infection, regardless of immune cell count.
• Have had a stem cell transplant or CAR-T therapy within the last 60 days.
• Have active hepatitis B or C.
• Have an active cytomegalovirus (CMV) infection.
• Have uncontrolled immune-related blood disorders like ITP or AIHA.
• Have significant heart disease.
• Have received a live vaccine within the last 28 days.
• Have allergies to any components of the study drugs or have had significant allergic reactions to Rituximab or Allopurinol.